Vmn2r60 Inhibitors
Vmn2r60 can exert their inhibitory effects through various molecular interactions with components of cellular signaling pathways. Olmutinib, gefitinib, erlotinib, and lapatinib are examples of such inhibitors that target the epidermal growth factor receptor (EGFR). By blocking the EGFR pathway, these inhibitors can interfere with the downstream signaling events in which Vmn2r60 is involved. Olmutinib, specifically, binds to the EGFR tyrosine kinase domain, leading to a cessation of the EGFR-mediated cellular responses that Vmn2r60 may be a part of. Similarly, gefitinib and erlotinib also inhibit the kinase activity of EGFR, thereby reducing the signal transduction processes associated with Vmn2r60. Lapatinib extends this action by additionally inhibiting HER2/neu tyrosine kinase, which is implicated in pathways that could intersect with Vmn2r60 function.
Sorafenib, sunitinib, and pazopanib act on multiple tyrosine protein kinases such as VEGFR, PDGFR, c-Kit, and Raf kinases. The inhibition of these kinases by sorafenib, for example, can lead to a decrease in the signaling activity where Vmn2r60 may play a role. Sunitinib and pazopanib, by hindering the kinase activity of VEGFR and PDGFR, can disrupt the angiogenesis and cell proliferation pathways potentially linked to Vmn2r60. Dasatinib broadens the spectrum of inhibition by targeting BCR-ABL and Src family kinases, which could indirectly affect Vmn2r60 signaling. Vandetanib and axitinib, by inhibiting their respective targets (VEGFR, EGFR, and RET for vandetanib and VEGFR for axitinib), also contribute to the diminishing of Vmn2r60 signaling capacity. Crizotinib and nilotinib further expand the list of inhibitors by targeting ALK, ROS1, and BCR-ABL tyrosine kinases, respectively, which can alter the pathways associated with Vmn2r60, leading to reduced signaling activity of this protein.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib targets the epidermal growth factor receptor (EGFR) tyrosine kinase, which may be involved in the signaling pathway of Vmn2r60. By inhibiting EGFR, gefitinib could reduce Vmn2r60 mediated signal transduction. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib is another EGFR tyrosine kinase inhibitor that can impede downstream signaling pathways where Vmn2r60 may play a role. This inhibition can lead to decreased activity of Vmn2r60-dependent processes. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Lapatinib can inhibit both EGFR and HER2/neu tyrosine kinases. HER2/neu is a part of pathways that could intersect with Vmn2r60 function, and its inhibition may lead to reduced Vmn2r60 activity. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib targets multiple tyrosine protein kinases, such as VEGFR, PDGFR, and Raf kinases. These pathways may interact with the signaling processes involving Vmn2r60, and their inhibition could decrease Vmn2r60 signaling. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib inhibits receptor tyrosine kinases including PDGFR and VEGFR, which are part of angiogenesis and cell proliferation pathways that could be linked to Vmn2r60 signaling, potentially diminishing its activity. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor affecting BCR-ABL and Src family kinases. By inhibiting these kinases, it may indirectly inhibit signaling pathways in which Vmn2r60 is involved, leading to decreased functional activity. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Vandetanib inhibits VEGFR, EGFR, and RET tyrosine kinases. By inhibiting these kinases, it could limit the signaling capacity of pathways that Vmn2r60 is part of, resulting in functional inhibition. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $130.00 $182.00 | 2 | |
Pazopanib is an inhibitor of multiple tyrosine kinases including VEGFR, PDGFR, and c-Kit. These kinases are part of signaling networks that Vmn2r60 may be involved in, and their inhibition could reduce Vmn2r60 signaling efficacy. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $209.00 $413.00 | 9 | |
Nilotinib inhibits BCR-ABL tyrosine kinase which could be linked to pathways involving Vmn2r60. By inhibiting BCR-ABL, nilotinib may cause a decrease in Vmn2r60-associated signaling. | ||||||